Tikcro Technologies Ltd. (OTC PK:TIKRF) today reported results for the third quarter ended September 30, 2013.
Net profit for the third quarter was $386,000, or $0.04 per diluted share. Results for the third quarter included financial profit of approximately $590,000 that resulted mainly from the receipt of shares of BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment, that were awarded to Tikcro pursuant to an arbitration award in July 2013. Excluding this gain, net loss for the third quarter was $204,000 or $0.02 per diluted share.
Help employers find you! Check out all the jobs and post your resume.
